The pharmacological management of cognitive dysfunction in Alzheimer's disease.
Vandewoude
M F
MF
Universitair Centrum Geriatrie Antwerpen. maurits.vandewoude@ocmw.antwerpen.be of vdwoude@uia.ua.ac.be
D000109:Acetylcholine / Q000627:therapeutic use; D000544:Alzheimer Disease / Q000188:drug therapy*; D000682:Amyloid / Q000037:antagonists & inhibitors; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003072:Cognition Disorders / Q000188:drug therapy*; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D009414:Nerve Growth Factors / Q000627:therapeutic use; D011355:Prodrugs / Q000627:therapeutic use
D000682:Amyloid; D000893:Anti-Inflammatory Agents; D002800:Cholinesterase Inhibitors; D009414:Nerve Growth Factors; D011355:Prodrugs; D000109:Acetylcholine